Navigation Links
Genalyte Awarded $500,000 SBIR Grant To Develop Multiplexed Assays For Early Detection And Monitoring Of Type 1 Diabetes
Date:12/11/2012

SAN DIEGO, Dec. 11, 2012 /PRNewswire/ -- Genalyte, Inc. today announced that it has been awarded a Small Business Innovation Research (SBIR) grant to develop multiplexed diagnostic assays for the early detection and monitoring of Type 1 diabetes that will run on Genalyte's innovative MaverickTMDetection System.  The $500,000 grant is from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health.  Genalyte's novel multiplexing technology simultaneously screens for the detection of multiple autoantibodies and other proteins using a one-step, 15-minute process. 

The SBIR-funded program initially will create a basic multiplexed assay to detect autoimmune response for known targets for Type 1 diabetes.  It will then expand the approach to profile autoantibody response by multiple criteria, which is expected to enhance the ability of researchers and clinicians to detect and monitor the development of the disease.

"The pioneering work of the late Dr. Eisenbarth and others established that the development of Type 1 diabetes is an incremental process, as rogue elements of the immune system over time compromise and eventually destroy the pancreatic islet cells that produce insulin," noted Martin Gleeson, PhD, Chief Scientific Officer of Genalyte.  "The unique capabilities of our Maverick multiplexed detection platform have the potential to provide researchers and clinicians with the tools to detect and track this process from a very early stage, when therapeutic intervention to interrupt the process could be feasible."

Once the autoantibody panels have been developed and tested, they will be refined and validated using samples from patients with Type 1 diabetes.  Genalyte expects to collaborate on this phase of the project with researchers from Dr. Eisenbarth's laboratory at the Barbara Davis Diabetes Center of the University of Colorado School of Medicine in Denver.

Dr. Gleeson added, "From early on we envisioned that the unprecedented multiplexing capabilities of our Maverick technology would make it possible to change the way that certain diseases are diagnosed and treated.  We are delighted that NIDDK is supporting development of these assays that have the potential to make this goal a reality for the millions of individuals at risk of Type 1 diabetes."

Genalyte's Maverick Detection System uses a silicon chip containing arrays of photonic ring sensors that simultaneously analyze multiple antibodies and other proteins from a single small sample.  The Maverick system's one-step approach automates the washes, incubations, reagent processing and other steps needed for the analysis.  Semi-quantitative results are reported for each analyte, eliminating the need for reflex testing.  The Maverick platform has a large dynamic range and excellent sensitivity, with outstanding reproducibility.

The Maverick Detection System and its ENA 4 and ENA 6 Assay Kits are currently commercially available.  They simultaneously screen for several of the most common antibodies found in autoimmune connective tissue disorders, such as lupus (SLE), Sjogren's syndrome, and scleroderma.  The assay results are highly reproducible, show excellent correlation to ELISA and are up to ten times more sensitive.  Assay kits for advanced SLE testing, rheumatoid arthritis and Type I diabetes are available under the Genalyte Technology Access program. 

For more information about the Maverick platform and Genalyte's new Custom Chip Spotting Service, visit www.genalyte.com.  Maverick assays are currently available for research use only.

About Genalyte
Founded in 2007, Genalyte, Inc. is commercializing the MaverickTM detection platform based on the company's revolutionary Microring Sensor TechnologyTM a new approach to multiplexing that leverages advances in silicon photonics to reduce or eliminate sample preparation, provide scalable multiplexing for both proteins and nucleic acids from a single small sample, and achieve excellent sensitivity and up to eight logs of dynamic range.Contacts:Genalyte, Inc.

Media:Martin Gleeson, PhD

BLL Partners, LLCChief Scientific Officer

Barbara Lindheim+1 858 750-4470

+1 212 584-2276martin@genalyte.com

blindheim@bllbiopartners.com


'/>"/>
SOURCE Genalyte, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Florida Blue Awarded Certified Center of Excellence by BenchmarkPortal for Second Consecutive Year
2. Artemis Diagnostics awarded two grants from Technology Strategy Board to develop cancer imaging technology
3. Elbit Imaging Ltd. Announces InSightecs ExAblate Neuro System Awarded European CE Mark for Non-invasive Treatment of Neurological Disorders in the Brain
4. Sigma-taus Antimalarial Awarded "Project of the Year" 2011 by Medicines for Malaria Venture
5. Daniels Sharpsmart Canada Awarded HealthPro Contract And Appoints Daniel Kennedy CEO Of Daniels Canada
6. Key patent awarded to Adjuvance co-founders for pioneering method of producing rare vaccine component.
7. Breast Cancer Survivor Awarded Top Prize In 2012 Oncology On Canvas(SM) Art Competition
8. New Snoring Therapy Awarded The Prestigious Spark Award
9. Harrisvaccines Awarded Vaccine Product Licensure
10. Healionics Awarded $900k Grant from NIH
11. Eutropics Pharmaceuticals awarded NCI contract to develop companion diagnostic for guiding AML treatments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/31/2016)... 2016 PaperHive Will Enable ... Elsevier,s ScienceDirect Database Elsevier , ... information products and services, today announced it will ... collaboration platform PaperHive to enable researchers to easily discover, ... on ScienceDirect , the world,s largest database ...
(Date:5/31/2016)... , Isansys  Lifecare, a new generation digital healthcare company, ... patient monitoring platform, as it ships more systems to hospitals in ... Scotland and Norway , ... earlier this year, is now being used in ground-breaking clinical ... new technology significantly enhances the user experience and provides higher ...
(Date:5/30/2016)... York , May 30, 2016 ... report titled, "Advanced (3D/4D) Visualization Systems Market - Global ... - 2024." According to the report, the global advanced ... Bn in 2015 and is anticipated to expand at ... reach US$ 3.2 Bn in 2024. Advanced ...
Breaking Medicine Technology:
(Date:5/31/2016)... ... May 31, 2016 , ... ... announced it has been included by Gartner, Inc. in the Contact Center Infrastructure ... of Contact Center Infrastructure technologies, some of which include: Computer-telephony integration (CTI)/Web ...
(Date:5/31/2016)... ... May 31, 2016 , ... The University of ... Intelligence (AI) and the latest in Clinical Patient Pod (CPP) technologies ... analytic outputs directly into the clinical workflow. These insights are empowering the more ...
(Date:5/31/2016)... (PRWEB) , ... May 31, 2016 , ... ... commercial molecular diagnostics device that enables unprecedented portability and convenience. , The Cube ... four inches cubed in size, the Cube fits easily into any space, whether ...
(Date:5/31/2016)... ... May 31, 2016 , ... The Global Wellness Summit ... predictions on the future of wellness, travel, spa and beauty in Europe. The organization ... beauty companies to leading economists and researchers - to forecast where wellness is headed ...
(Date:5/31/2016)... ... May 31, 2016 , ... The Orthopaedic Research and Education Foundation ... , David G. Lewallen, MD, began his term as president in March, succeeding John ... MD, is OREF’s new president-elect. Richard F. Kyle, MD, will serve as chair, corporate ...
Breaking Medicine News(10 mins):